Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11392894 | 0.88 | CA2 (0.39) | CA2CA9SRC | |
| SCHEMBL11320245 | 0.81 | IDO1 (0.41) | CA2CA9SRC | |
| SCHEMBL11316154 | 0.81 | ESR1 (0.42) | CA2CA9SRC | |
| SCHEMBL437438 | 0.79 | IDO1 (0.50) | CA2 | |
| SCHEMBL11349144 | 0.78 | CA12 (0.31) | CA9 | |
| SCHEMBL9881633 | 0.77 | CA2 (0.32) | CA2CA9SRC | |
| SCHEMBL17321077 | 0.77 | TRPA1 (0.39) | CA2CA9SRC | |
| SCHEMBL177564 | 0.77 | ALDH1A1 (0.44) | CA2CA9 | |
| SCHEMBL513967 | 0.77 | CYP3A4 (0.52) | — | |
| SCHEMBL18544386 | 0.77 | LTA4H (0.39) | CA2CA9SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-11-04 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010045598-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CA2 1100/4885CA9 497/4885SRC 1529/4885 |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | CA2 2790/4885CA9 3577/4885SRC 2574/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | CA2 2485/4885CA9 1844/4885SRC 3275/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | CA2 2781/4885CA9 507/4885SRC 3047/4885 |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | CA2 3559/4885CA9 1645/4885SRC 2313/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | CA2 2222/4885CA9 3374/4885SRC 1141/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA2 1961/4885CA9 121/4885SRC 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.